Samsung Bioepis And Phrontline Announce a Global Strategic Partnership to Advance Best-in-Class Antibody-Drug Conjugate Therapeutics for Solid Tumors
Business Wire India Samsung Bioepis and Phrontline will co-develop two investigational antibody-drug conjugate (ADC) assets directed against targets expressed in a broad range of cancers Collaboration will add a new class of bispecific and dual-payload…
